{"id":"NCT01941940","sponsor":"Hoffmann-La Roche","briefTitle":"A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants","officialTitle":"A National, Open-Label, Single-Arm, Phase IIIb Study to Evaluate the Efficacy of Weekly Tocilizumab Subcutaneous, Administered as Monotherapy or in Combination With Methotrexate and/or Other DMARDs in Rheumatoid Arthritis (RA) Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-09-05","primaryCompletion":"2015-09-09","completion":"2016-07-05","firstPosted":"2013-09-13","resultsPosted":"2016-12-15","lastUpdate":"2017-07-11"},"enrollment":227,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Tocilizumab","otherNames":["RoActemra"]},{"type":"DRUG","name":"DMARDs","otherNames":[]}],"arms":[{"label":"Tocilizumab","type":"EXPERIMENTAL"}],"summary":"This open-label, single arm, Phase 3b study will evaluate the efficacy of tocilizumab (RoActemra), administered as monotherapy or in combination with methotrexate and/or other DMARDs, in participants with moderate to severe active RA.","primaryOutcome":{"measure":"Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24","timeFrame":"Baseline, Week 24","effectByArm":[{"arm":"Tocilizumab","deltaMin":-21.6,"sd":13.25}],"pValues":[{"comp":"OG000","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":19},"locations":{"siteCount":49,"countries":["Italy"]},"refs":{"pmids":["30649524","29244149"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":227},"commonTop":["Influenza","Cough","Transaminases increased","Bronchitis","Urinary tract infection"]}}